Browse result page of THPdb

The total number entries retrieved from this search are 14

ID	ThPPID	Name	Peptide Sequence	Length	Functional Classification	Disease	Brand	Company	Physical Appearance	Route of Administartion	Category	Target
ID1403	ThPPIDTh1065	NameDigoxin Immune Fab (Ovine)	Peptide SequenceHeavy Chain: EVQLQQS Full view	Length438	Functional ClassificationIIa	DiseaseCardiac	BrandDIGIBIND	CompanyGalaxo Smith Kline	Physical AppearanceSterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep.	Route of AdministartionIntravenous infusion after reconstitution with Sterile Water for Injection	CategoryAntidotes	TargetT-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
ID1404	ThPPIDTh1065	NameDigoxin Immune Fab (Ovine)	Peptide SequenceHeavy Chain: EVQLQQS Full view	Length438	Functional ClassificationIIa	DiseaseCardiac	BrandDigiFab	Company Protherics Inc	Physical AppearanceSterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments.ÂÂÂ	Route of AdministartionIntravenous administrationÂÂÂ	CategoryAntidotes	TargetT-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
ID1454	ThPPIDTh1084	NameBecaplermin	Peptide SequenceSLGSLTIAEPAMIAECKTRT Full view	Length109	Functional ClassificationIb	DiseaseCardiac	BrandREGRANEX	CompanyOMJ Pharmaceuticals, Inc. San German, Puerto Rico	Physical AppearanceGel: 0.01 %; clear, colorless to straw-colored gel	Route of AdministartionExternal use only	CategoryAngiogenesis Inducing Agents	TargetT-cell surface glycoprotein CD1a,Major histocompatibility complex class I-related gene protein,Integrin alpha-L,T-lymphocyte activation antigen CD86,Low affinity immunoglobulin gamma Fc region receptor II-b,T-cell surface glycoprotein CD4,Integrin beta-1,Integrin alpha-V,Integrin beta-3
ID1468	ThPPIDTh1091	NameBevacizumab	Peptide SequenceDIQMTQSPSSLSASVGDRVT Full view	Length214	Functional ClassificationIIa	DiseaseCardiac	BrandAvastin	CompanyGenentech	Physical AppearanceSlightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion	Route of AdministartionIntravenous infusion	CategoryAngiogenesis Inhibitors	TargetInterleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c
ID1530	ThPPIDTh1109	NameNesiritide	Peptide SequenceSPKMVQGSGCFGRKMDRISS Full view	Length32	Functional ClassificationIb	DiseaseCardiac	BrandNATRECOR	CompanyScios unit of Johnson & Johnson,	Physical AppearanceWhite- to off-white lyophilized powder	Route of AdministartionIntravenous injection	CategoryN.A.	TargetN.A.
ID1678	ThPPIDTh1162	NameAlirocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIc	DiseaseMetabolic/Cardiac	BrandPraluent	CompanySanofi Aventis U.S. Llc	Physical AppearanceInjection, Solution	Route of AdministartionSubcutaneous	CategoryN.A.	TargetProprotein convertase subtilisin/kexin type 9
ID1679	ThPPIDTh1162	NameAlirocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIc	DiseaseMetabolic/Cardiac	BrandPraluent	CompanySanofi Aventis Canada Inc	Physical AppearanceSolution	Route of AdministartionSubcutaneous	CategoryN.A.	TargetProprotein convertase subtilisin/kexin type 10
ID1680	ThPPIDTh1162	NameAlirocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIc	DiseaseMetabolic/Cardiac	BrandPraluent	CompanySanofi Aventis Canada Inc	Physical AppearanceSolution	Route of AdministartionSubcutaneous	CategoryN.A.	TargetProprotein convertase subtilisin/kexin type 11
ID1681	ThPPIDTh1162	NameAlirocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIc	DiseaseMetabolic/Cardiac	BrandPraluent	CompanySanofi Aventis U.S. Llc	Physical AppearanceInjection, Solution	Route of AdministartionSubcutaneous	CategoryN.A.	TargetProprotein convertase subtilisin/kexin type 14
ID1741	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandNA	CompanyNA	Physical AppearanceInjection, Solution; Injection	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 9
ID1742	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandRepatha	CompanyAmgen Inc	Physical AppearanceInjection, Solution	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 10
ID1743	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandRepatha	CompanyAmgen Canada Inc	Physical AppearanceSolution	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 11
ID1744	ThPPIDTh1179	NameEvolocumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseGenetic/Metabolic/Cardiac	BrandRepatha	CompanyAmgen Inc	Physical AppearanceInjection, Solution	Route of AdministartionSubcutaneous	CategoryLipid Modifying Agents, Plain; Cardiovascular System	TargetProprotein convertase subtilisin/kexin type 12
ID1831	ThPPIDTh1221	NameC1 Esterase Inhibitor (Recombinant)	Peptide SequenceNA Full view	Length0	Functional ClassificationIIa	DiseaseCardiac Disorders	BrandRuconest	CompanyTjoapack Netherlands Bv	Physical AppearancePowder and liquid for solution	Route of AdministartionIntravenous	CategoryBlood and Blood Forming Organs	TargetComplement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator